🚀 VC round data is live in beta, check it out!
Gen İlaç Valuation Multiples
Discover revenue and EBITDA valuation multiples for Gen İlaç and similar public comparables like Pacira BioSciences, Evommune, Philogen, Ventyx Biosciences and more.
Gen İlaç Overview
About Gen İlaç
Gen Ilac Ve Saglik Urunleri Sanayi ve Ticaret AS is a specialty pharmaceuticals company in Turkey. Its locally manufactured products include Cajex, Contra-K, Epamor, Genkort, Ilopera, among others, while imported products include AvonexPEN, Plegridy, Tecfidera, Regen-D among others.
Founded
1987
HQ
Employees
563
Website
Sectors
Financials (FY)
EV
$1B
Gen İlaç Financials
Gen İlaç reported last fiscal year revenue of $428M and EBITDA of $66M.
In the same fiscal year, Gen İlaç generated $90M in gross profit, $66M in EBITDA, and $18M in net income.
Gen İlaç P&L
In the most recent fiscal year, Gen İlaç reported revenue of $428M and EBITDA of $66M.
Gen İlaç expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $428M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $90M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 21% | XXX | XXX | XXX |
| EBITDA | — | XXX | $66M | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 15% | XXX | XXX | XXX |
| EBIT Margin | — | XXX | 13% | XXX | XXX | XXX |
| Net Profit | — | XXX | $18M | XXX | XXX | XXX |
| Net Margin | — | XXX | 4% | XXX | XXX | XXX |
| Net Debt | — | — | $68M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Gen İlaç Stock Performance
Gen İlaç has current market cap of $1B, and enterprise value of $1B.
Market Cap Evolution
Gen İlaç's stock price is $0.22.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1B | $1B | -2.9% | XXX | XXX | XXX | $0.00 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialGen İlaç Valuation Multiples
Gen İlaç trades at 2.4x EV/Revenue multiple, and 15.6x EV/EBITDA.
Gen İlaç Financial Valuation Multiples
As of April 21, 2026, Gen İlaç has market cap of $1B and EV of $1B.
Equity research analysts estimate Gen İlaç's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Gen İlaç has a P/E ratio of 55.5x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 2.4x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 15.6x | XXX | XXX | XXX |
| EV/EBIT | — | XXX | 18.7x | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 11.5x | XXX | XXX | XXX |
| P/E | — | XXX | 55.5x | XXX | XXX | XXX |
| EV/FCF | — | XXX | 92.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Gen İlaç Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Gen İlaç Margins & Growth Rates
Gen İlaç's revenue in the last fiscal year grew by 30%.
Gen İlaç's revenue per employee in the last FY averaged $0.8M, while opex per employee averaged $0.1M for the same period.
Gen İlaç Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | 30% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 15% | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 101% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.8M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 3% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 1% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 4% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 8% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Gen İlaç Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Gen İlaç | XXX | XXX | XXX | XXX | XXX | XXX |
| Pacira BioSciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Evommune | XXX | XXX | XXX | XXX | XXX | XXX |
| Philogen | XXX | XXX | XXX | XXX | XXX | XXX |
| Ventyx Biosciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Geron | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Gen İlaç M&A Activity
Gen İlaç acquired XXX companies to date.
Last acquisition by Gen İlaç was on XXXXXXXX, XXXXX. Gen İlaç acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Gen İlaç
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialGen İlaç Investment Activity
Gen İlaç invested in XXX companies to date.
Gen İlaç made its latest investment on XXXXXXXX, XXXXX. Gen İlaç invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Gen İlaç
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Gen İlaç
| When was Gen İlaç founded? | Gen İlaç was founded in 1987. |
| Where is Gen İlaç headquartered? | Gen İlaç is headquartered in Turkey. |
| How many employees does Gen İlaç have? | As of today, Gen İlaç has over 563 employees. |
| Is Gen İlaç publicly listed? | Yes, Gen İlaç is a public company listed on Borsa Istanbul. |
| What is the stock symbol of Gen İlaç? | Gen İlaç trades under GENIL ticker. |
| When did Gen İlaç go public? | Gen İlaç went public in 2021. |
| Who are competitors of Gen İlaç? | Gen İlaç main competitors are Pacira BioSciences, Evommune, Philogen, Ventyx Biosciences. |
| What is the current market cap of Gen İlaç? | Gen İlaç's current market cap is $1B. |
| What is the current revenue of Gen İlaç? | Gen İlaç's last fiscal year revenue is $428M. |
| What is the current EV/Revenue multiple of Gen İlaç? | Current revenue multiple of Gen İlaç is 2.4x. |
| Is Gen İlaç profitable? | No, Gen İlaç is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.